Volver al Panel







Veradermics, Incorporated (MANE)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
MANE Intraday
No data available
SímboloMANE
Fecha de SalidaFeb 4, 2026
CEODr. Reid Waldman M.D.
Empleados a Tiempo Completo37
SectorHealthcare
IndustriaBiotechnology
PaísUnited States
BolsaNYSE
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | +12.36% | +13.45 US$ |
| 5 Días | +7.75% | +8.79 US$ |
| 1 Mes | +14.53% | +15.52 US$ |
| 6 Meses | +73.89% | +51.96 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de MANE...
Estadísticas Clave
Cap. de Mercado
5.11B
Relación P/E
N/A
Rend. de Div.
0.00%
Máx. 52 Semanas
$136.72
Mín. 52 Semanas
$32.00
Consenso de Analistas
CONSENSOCompra Fuerte
ALCISTA7100.0%
NEUTRAL00.0%
BAJISTA00.0%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$135.00
$135.00
Objetivo Máx.
$182.00
$182.00
Actual$122.27
Objetivo Prom.$164.83
Recomendaciones de Analistas
Precio Objetivo:$164.83($135.00 - $182.00)
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre MANE
Únase a la comunidad para compartir su análisis
Últimas Noticias para MANE

Veradermics’ stock up on male hair loss trial success
Clinical Trials Arena•19 oct 2026, 17:18
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” Treatment
TIKR•19 oct 2026, 17:07

Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth Results
MarketBeat•19 oct 2026, 17:02
Veradermics stock surges as hair loss drug meets Phase 3 goals
Investing.com•19 oct 2026, 13:50
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness study
BioPharma Dive•19 oct 2026, 13:14


Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
Insider Monkey•12 sept 2026, 00:29
Veradermics to Present at Upcoming September Investor Conferences
Business Wire•3 sept 2026, 21:33

Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
Simply Wall St.•3 sept 2026, 01:06